Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

OTHER × Leiomyosarcoma × lenvatinib × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Carcinoma, Hepatocellular 99 Cholangiocarcinoma 22 Carcinoma, Renal Cell 16 Liver Neoplasms 10 Biliary Tract Neoplasms 9 Stomach Neoplasms 8 Endometrial Neoplasms 7 Breast Neoplasms 7 Thyroid Neoplasms 6 Neoplasms 6 Recurrence 5 Uterine Cervical Neoplasms 4 Melanoma 4 Thyroid Cancer, Papillary 3 Pancreatic Neoplasms 3 Ovarian Neoplasms 3 Neuroendocrine Tumors 3 Neoplasm Metastasis 3 Cirrhosis, Familial, with Pulmonary Hypertension 3 Advanced Biliary Tract Cancer 3 Adenocarcinoma, Follicular 3 Adenocarcinoma 3 Uveal Melanoma 2 Thyroid Carcinoma, Anaplastic 2 Small Cell Lung Carcinoma 2 Sarcoma 2 Paraganglioma, Extra-Adrenal 2 Mesothelioma, Malignant 2 Liver Diseases 2 Kidney Neoplasms 2

Interventions

Gemcitabine 14 Docetaxel 8 Doxorubicin 7 Radiotherapy 6 Trabectedin 5 pazopanib 4 Sunitinib 3 Nivolumab 3 Dacarbazine 3 liposomal doxorubicin 2 eribulin 2 avelumab 2 Specimen Handling 2 Radiation Dose Hypofractionation 2 Letrozole 2 Ifosfamide 2 Bevacizumab 2 3-(5-fluorobenzofuran-3-yl)-4-(5-methyl-5H-(1,3)dioxolo(4,5-f)indol-7-yl)-pyrrole-2,5-dione 2 tremelimumab 1 temsirolimus 1 sotigalimab 1 selinexor 1 sargramostim 1 ribociclib 1 regorafenib 1 pembrolizumab 1 pegfilgrastim 1 niraparib 1 lenvatinib 1 lentiviral minigene vaccine of COVID-19 coronavirus 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT03526679 2025-12-05

LEADER

National Taiwan University Hospital

Phase 1/2 Completed

30 enrolled 9 charts

Leiomyosarcoma, Liposarcoma, Sarcoma

Data powered by HemOnc (CC BY 4.0) Colophon ⚡